Sabrina Rossi1, Vincenzo Di Noia2, Laura Tonetti3, Antonia Strippoli2, Michele Basso2, Giovanni Schinzari2, Alessandra Cassano1, Antonio Leone3, Carlo Barone2, Ettore D'Argento2. 1. Department of Oncology & Hematology, Humanitas Clinical & Research Center, Via Manzoni 56, 20089 Rozzano (MI), Italy. 2. Polo Scienze Oncologiche ed Ematologiche, UOC di Oncologia Medica, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli - Largo Francesco Vito 1, 00168 Rome, Italy. 3. Polo Scienze delle Immagini, di Laboratorio ed Infettivologiche, Instituto di Radiologia, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli - Largo Francesco Vito 1, 00168 Rome, Italy.
Abstract
AIM: To evaluate gefitinib outcomes in EGFR-mutated non-small-cell lung cancer (NSCLC) patients harboring EGFR mutations, according to their sarcopenia status. PATIENTS & METHODS: We retrospectively evaluated 33 patients with advanced NSCLC and EGFR mutations (exon 19 or 21), dividing them into sarcopenic patients, with low skeletal muscle index ≤39 cm2/m2 for women and ≤55 cm2/m2 for men, and nonsarcopenic patients. RESULTS: Sarcopenia does not affect response to gefitinib treatment in EGFR mutated NSCLC patients, even if it is a bad prognostic indicator for overall survival (p = 0.035). CONCLUSION: Early recognition of sarcopenia is beneficial for prevention of cancer cachexia and detection of patients at potential risk of serious adverse events. Gefitinib dosage should be reduced and modulated in sarcopenic patients.
AIM: To evaluate gefitinib outcomes in EGFR-mutated non-small-cell lung cancer (NSCLC) patients harboring EGFR mutations, according to their sarcopenia status. PATIENTS & METHODS: We retrospectively evaluated 33 patients with advanced NSCLC and EGFR mutations (exon 19 or 21), dividing them into sarcopenic patients, with low skeletal muscle index ≤39 cm2/m2 for women and ≤55 cm2/m2 for men, and nonsarcopenic patients. RESULTS:Sarcopenia does not affect response to gefitinib treatment in EGFR mutated NSCLCpatients, even if it is a bad prognostic indicator for overall survival (p = 0.035). CONCLUSION: Early recognition of sarcopenia is beneficial for prevention of cancer cachexia and detection of patients at potential risk of serious adverse events. Gefitinib dosage should be reduced and modulated in sarcopenic patients.
Entities:
Keywords:
BMI; NSCLC; cachexia; gefitinib; sarcopenia; skeletal muscle index
Authors: Hakan Kardas; Maximilian Thormann; Caroline Bär; Jazan Omari; Andreas Wienke; Maciej Pech; Alexey Surov Journal: In Vivo Date: 2022 Jan-Feb Impact factor: 2.155
Authors: Marco Gallo; Valerio Adinolfi; Viola Barucca; Natalie Prinzi; Valerio Renzelli; Luigi Barrea; Paola Di Giacinto; Rosaria Maddalena Ruggeri; Franz Sesti; Emanuela Arvat; Roberto Baldelli; Emanuela Arvat; Annamaria Colao; Andrea Isidori; Andrea Lenzi; Roberto Baldell; M Albertelli; D Attala; A Bianchi; A Di Sarno; T Feola; G Mazziotti; A Nervo; C Pozza; G Puliani; P Razzore; S Ramponi; S Ricciardi; L Rizza; F Rota; E Sbardella; M C Zatelli Journal: Rev Endocr Metab Disord Date: 2020-10-06 Impact factor: 6.514